NA 831
Lewy Body Dementia
Biomed Industries, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
33 Active assets in the Lewy Body Dementia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Memantine Zealand University Hospital | Phase 4 | BBB |
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) Virginia Commonwealth University | Phase 4 | BB |
Armodafinil NYU Langone Health | Phase 4 | BB |
Dapagliflozin Mayo Clinic | Phase 4 | BB |
Sitagliptin Mayo Clinic | Phase 4 | BB |
View all 49 →
Same molecule, other indications
NA 831 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →